knowledge -WSS

knowledge

author：explore 2025-09-30 12:17:21 - browse：625

Light hits on the portrait of George Washington on a one dollar bill. The portrait is surrounded by white and red tablets coming out of a pill bottle, as well as some coins — coverage from STAT — Adobe

WASHINGTON — Pharmaceutical companies are doing anything they can to stop President Biden’s Medicare program from being able to negotiate prices for their products, including suing the government. Experts say their efforts might actually benefit Biden by reminding voters that he’s taking on big drug companies.

When Democrats passed a law directing Medicare to negotiate drug prices, it was considered a major achievement. The new law, two decades in the making, gives Biden an accomplishment to both tout for himself and criticize Republicans for opposing — no Republicans voted to let Medicare negotiate drug prices.

Medicare price negotiation is popular with voters, as are the law’s price-inflation limits, and it includes additional, direct benefits for older adults that are easy to understand. It caps annual out-of-pocket retail-drug spending for seniors and people with disabilities, and it caps their monthly spending on insulin at $35.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Impact of Dobbs ruling felt at reproductive medicine meeting

knowledge

WSS

UnitedHealth’s board chair also owns a personal investment firm

Medicare Advantage today, explained in one chart

STAT Summit: GSK CEO on pharma giant's new direction

EU regulator recommends expanding Mounjaro approval to obesity

STAT Summit: Biotech founders on deal

Copay coupons to count toward deductibles, after Biden court move

focus

knowledge

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Parkinson’s finding may lead to tests and, someday, treatments

Hollywood unions extend contract negotiations for actors

Readout Newsletter: Merck, J&J, and long Covid

ChatGPT in medicine: STAT answers readers' burning questions

Lawmakers consider Medicare pay reforms for doctors

What does generative AI mean for health care? We asked experts

Prior authorization will have to move faster under new Biden rule

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Think you might have Covid

entertainment

My yearlong odyssey to get my son’s ADHD medication covered

Studies point to risks of excluding people with obesity from drug trials

Impact of Dobbs ruling felt at reproductive medicine meeting

The EU Joint Clinical Assessment needs to live up to its promise

NIH confirmation hearing shows politicization of research

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

hotspot

knowledge

knowledge

focus